Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

Executive Summary

Medicare’s current approach to inpatient CAR-T reimbursement in 2019 would lead to an $186,500 shortfall for providers per patient, stakeholders estimate.

You may also be interested in...



Could Outpatient Cell Therapies Provide Way Out Of Bundled Payment Trap?

Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.

Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances

CAR-T reimbursement is concern for former US FDA commissioner Scott Gottlieb in speech at the National Press Club.

Medicare Weighing Higher Add-On Payments For New Drugs, Including CAR-T

Change would increase maximum new technology add-on payments from 50% to 65% of costs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel